Quadrivalent influenza split vaccine high- vs low-dose in children 6–35 months

Phase 3, randomised, double-blind trial of influenza vaccine (split virion, inactivated, quadrivalent) in influenza A virus infection (H1N1), influenza A H3N2 (H3N2) and influenza B (2 arms), sponsored by Anhui Zhifei Longcom Biopharmaceutical. Primary endpoints: Seroconversion rate, GMT, seroprotection rate, and GMI for H1N1, H3N2, B(V), and B(Y) hemagglutination inhibition antibodies 30 days after completion of vaccination, Incidence and severity of all adverse events from first dose to 30 days after completion of vaccination and 4 more. Started Dec 2022; status: completed.